Stay updated with breaking news from Christian Ottmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The biotechnology start-up Ambagon Therapeutics has raised 75 million euros (85 million dollars) in a financing round. With the money, the Dutch-American company will develop medicines that can be used to better treat cancer in the future. Ambagon was founded in 2020 on the basis of a number of years of research at TU Eindhoven by Eline Sijbesma, Loes Stevers and others.
Biotech startup Ambagon Therapeutics is taking a new approach to making elusive protein targets “druggable” by using molecular glues. The biotech has a pipeline of preclinical cancer drugs and it has raised $85 million to support their development.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Modular platform enables development of molecular glue stabilizers addressing intrinsically disordered proteins, a largely undrugged target classInitial discovery pipeline focused on high-value targets in oncologySAN FRANCISCO--(BUSINESS WIRE)--Ambagon Therapeutics, a biotechnology company unlocking intrinsically di...
The biotechnology start-up Ambagon Therapeutics has raised 75 million euro (85 million dollars) in a financing round. With the money, the